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Vitamin-D-binding protein (VDBP) is a low molecular weight protein that is filtered through
the glomerulus as a 25-(OH) vitamin D 3/VDBP complex. In the normal kidney VDBP is
reabsorbed and catabolized by proximal tubule epithelial cells reducing the urinary excre-
tion to trace amounts. Acute tubular injury is expected to result in urinary VDBP loss. The
purpose of our study was to explore the potential role of urinary VDBP as a biomarker of an
acute renal damage.
Method
We included 314 patients with diabetes mellitus or mild renal impairment undergoing coro-
nary angiography and collected blood and urine before and 24 hours after the CM applica-
tion. Patients were followed for 90 days for the composite endpoint major adverse renal
events (MARE: need for dialysis, doubling of serum creatinine after 90 days, unplanned
emergency rehospitalization or death).
Results
Increased urine VDBP concentration 24 hours after contrast media exposure was predictive
for dialysis need (no dialysis: 113.06 ± 299.61ng/ml, n = 303; need for dialysis: 613.07 ±
700.45 ng/ml, n = 11, Mean ± SD, p<0.001), death (no death during follow-up: 121.41 ±
324.45 ng/ml, n = 306; death during follow-up: 522.01 ± 521.86 ng/ml, n = 8; Mean ± SD,
p<0.003) and MARE (no MARE: 112.08 ± 302.00ng/ml, n = 298; MARE: 506.16 ± 624.61
ng/ml, n = 16, Mean ± SD, p<0.001) during the follow-up of 90 days after contrast media
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exposure. Correction of urine VDBP concentrations for creatinine excretion confirmed its
predictive value and was consistent with increased levels of urinary Kidney Injury Molecule-
1 (KIM-1) and baseline plasma creatinine in patients with above mentioned complications.
The impact of urinary VDBP and KIM-1 on MARE was independent of known CIN risk fac-
tors such as anemia, preexisting renal failure, preexisting heart failure, and diabetes.
Conclusions
Urinary VDBP is a promising novel biomarker of major contrast induced nephropathy-asso-
ciated events 90 days after contrast media exposure.
Introduction
Acute kidney injury (AKI) is a severe condition associated with a mortality of up to to 70%
[1,2,3,4,5] and prolonged hospitalitation increasing the costs of treatment [6].
Biomarkers that can predict the disease progression or development of life threatening com-
plications may help to better understand the disease pathways and to prevent complications.
During AKI, increased urinary excretion of different molecules may be caused by either
increased tubular secretion or impaired proximal tubular reabsorption [7,8,9]. Some biomark-
ers such as liver-type fatty acid-binding protein (L-FABP) and neutrophil gelatinase-associated
lipocalin (NGAL) are secreted by normal tubular cells into the urine, however, increased
amounts of those biomarkers in plasma of AKI patients [10] may also increase their urinary
concentration, causing misinterpretation. Vitamin-D-binding protein (VDBP) is a low molec-
ular weight protein that is filtered through the glomerulus as a 25-(OH) vitamin D 3/VDBP
complex and is uptaken by megalin receptors in the brush border of proximal tubule cells. The
carrier VDBP is degraded in lysosomes, while 25-(OH) vitamin D3 is converted into 1,25-
(OH)2 vitamin D3 and resecreted into the circulation (Fig 1) [11]. In the normal kidney,
VDBP is reabsorbed by megalin mediated endocytosis and catabolized by proximal tubule epi-
thelial cells reducing the urinary excretion to trace amounts [9].
Acute tubular necrosis (ATN) occurs already during the renal tubular epithelial cell injury
when renal blood flow decreases to a level resulting in severe cellular ATP depletion that in
turn leads to acute cell injury and dysfunction. Since receptor-mediated uptake of VDBP is
energy-consuming, tubular injury is expected to result in urinary VDBP loss [12]. While glo-
merular filtration rate (GFR) decrease can be diagnosed only hours after renal insult, increased
VDBP concentration may be detected as early as ATN occurs.
Administration of iodinated contrast media (CM) increases vasoconstriction and decreases
vasodilatation in the renal medulla, leading to hypoxia and even acute tubular necrosis known
as contrast-induced nephropathy (CIN) that tends to occur predominantly in diabetics and
patients with preexisting renal insufficiency [13].
It was previously shown that urinary VDBP concentration increases with increasing severity
of renal damage, and responded to renoprotective therapy [14]. Whether urine VDBP is related
to acute tubulointerstitial damage and long term prognosis of the kidney injury has not specifi-
cally been addressed so far. We investigated weather urinary VDBP concentration change
within the 48 hours after contrast media exposure are a potential predictor of adverse events
such as need for dialysis, doubling of serum creatinine, unplanned emergency rehospitalization
or death during three months of follow-up and development of contrast media induced
nephropathy (CIN). We also compared urinary VDBP and VDBP/urinary creatinine ratio
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(VDBP/uCr) with established tubular injury markers such as Kidney Injury Molecule-1 (KIM-




A prospective cohort of 314 consecutive patients underwent coronary angiography between
January 2010 and December 2011 in the Department of Cardiology of the Charité –Universi-
tätsmedizin Berlin. This study was specifically approved by the review board of our institution
and by the Ethics Commission of the Charité—Universitätsmedizin Berlin. Each participant of
the study has signed an informed consent form prior to involvement into the study. The
informed consent form was approved by the Ethics Commission of the Charité—Universitäts-
medizin Berlin. The study was conducted according to the Declaration of Helsinki, the Euro-
pean Guidelines on Good Clinical Practice, and relevant national and regional authority
requirements and ethics committees. Informed consent was obtained from each participant
prior to involvement into the study
2.1.1 Inclusion criteria. Consecutive patients with a high risk-profile of developing con-
trast induced renal failure, i.e. patients with plasma creatinine of at least 1.1 mg/dl but no dialy-
sis need or patients with preexisting diabetes mellitus independently of plasma creatinine level
were enrolled into the study. Inclusion criteria were based on Mehran contrast nephropathy
risk score [15].
2.1.2 Exclusion criteria. Patients with end-stage renal disease as well as patients who did
not sign an informative consent were excluded from the study.
2.2 Course of the study
After enrollment into the study, patients underwent blood- and urine sampling for obtaining
basal values. After that, paraclinical examination with contrast media was performed. In the
Fig 1. Model of megalin function in renal uptake and activation of 25-(OH) Vitamin D3. [11]
doi:10.1371/journal.pone.0145723.g001
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present study, only water-soluble, non-ionic, monomeric, low-osmolar, iodine-based contrast
agent Iobitridol was used in a concentration of 350 mg Jod/ml (XENETIX1 350, Guerbet
GmbH, Sulzbach/Taunus, Germany). Further, blood- and urine samples were obtained 24, 48
hrs and finally 3 months after contrast agent infusion (Fig 2).
2.3 Sample treatment and measurement
The samples were frozen at -80°C the very same day. Before freezing, blood samples were cen-
trifuged 5 minutes with 3000 rotates per minutes and only the plasma was frozen. Creatinine
was measured according to the method of Jaffé. GFR was estimated according to the modifica-
tion of diet in renal disease (MDRD) formula.
Human VDBP was measured with a commercially available sandwich ELISA (Quantikine
ELISA No. DVDBPO, R&D Systems, Inc. Minneapolis, USA), according to the manufacturer’s
instructions, see: https://resources.rndsystems.com/pdfs/datasheets/dvdbp0.pdf.
For the measurement of Kidney Injury Molecule-1 (KIM-1) in urine, KIM-1 ELISA TEST
KIT for the detection of KIM-1 in human (BioAssay Works1, L.L.C., Ijamsville, USA) was
used according to manufacturer instruction. Kim-1 antigen detection levels in urine greater
than 800 pg/ml were realized with a dose response relationship covering a three-log range.
2.4 Study endpoints
Study endpoints were death, initiation of dialysis, doubling of serum creatinine, non-elective
hospitalization and CIN during the 3 months follow-up. Additionally, incidences of major
adverse renal events (MARE) was assessed. CIN was defined as an increase of creatinine of
25% or 0.5 mg/dl from the baseline within 48 hours [16]. MARE was defined as an occurrence
of death, initiation of dialysis or a doubling of the creatinine at follow-up.
Fig 2. Course of the study.
doi:10.1371/journal.pone.0145723.g002
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2.5 Statistical analysis
The statistical analysis was made using SPSS 20 (IBM1 SPSS1 Statistics IBM Cooperation,
Armonk, USA). Differences among the biomarkers were estimated using the two-way analysis
of variance (ANOVA). Predictive values of the biomarkers were assessed using a logistic regres-
sion. Unless otherwise specified, all data are presented as Mean ± Standard Deviation (SD). For
all analyses a p< 0.05 was considered statistically significant.
Results
3.1 Patients characteristics
A total of 314 consecutive patients that underwent coronary angiography (239 (76.1%) men
and 75 (23.9%) women) with a mean age of 68.89 ± 9.69 years and a body mass index (BMI) of
28.99 ± 5.44 kg/m2 were enrolled into the study. 169 (53.8%) patients were previously diag-
nosed with diabetes mellitus, 81 (25.8%) suffered congestive heart failure and 86 (27.4%) had
an anemia (Table 1). The mean volume of injected contrast medium was 112.33 ± 55.24 ml.
The means of urinary VDBP and KIM-1 of the entire cohort prior to contrast media exposure
were12.80 ± 3515.23 ng/ml and 0.161 ± 0.19 ng/ml respectively. In addition, VDBP/urinary
Creatinine (VDBP/uCr) and KIM-1/urinary Creatinine (KIM-1/uCr) ratio as well as GFR were
calculated, and were at baseline 1.72 ± 1008.42; 0.026 ± 0.02 and 64.06 ± 21.05 ml/min/1.73 m2
respectively (Table 2). The New York Heart Association functional classification (NYHA) [17]
was used to grade the severity of functional limitations in a patient with heart failure. NYHA
class III/IV was defined as congestive heart failure. 65 patients had a NYHA class III and 16
patients had a NYHA class IV. Anemia was defined as hematocrit of less than 0.36 l/l for
females und less than 0.39 l/l for males.
Table 1. Patients characteristics at baseline. CM: contrast media, VDBP: vitamin D binding protein, KIM-
1: kidney injury molecule 1, uCr: urinary creatinine, CIN: contrast induced nephropathy, GFR: glomerulary fil-
tration rate estimated with the MDRD formula, ME: mean, M: mean, SD: standard deviation,*—p<0.05 is sta-
tistically significant.
Patients characteristics N 314
Female/male N (%) 75/239 (23.9/76.1)*
Age (ME±SD) Years 68.89 (±9.69)
Body mass index (ME±SD) kg/m2 28.99 (±5.44)
CM-volume (ME±SD) Ml 112.33 (±55.24)
Baseline plasma creatinine (ME±SD) mg/dl 1.24 (±0.43)
Baseline VDBP (ME±SD) ng/ml 12.80 (±3515.23)
Baseline KIM-1 (ME±SD) ng/ml 0.161 (±0.19)
Baseline VDBP/uCr (M±SD) ng/ml/mmol/l 1.72 (±1008.42)
Baseline KIM-1/uCr (M±SD) ng/ml/mmol/l 0.026 (±0.02)
Baseline GFR (ME±SD) ml/min/
1.73m2
64.06 (±21.05)
Diabetes mellitus N (%) 169 (53.8)
Congestive heart failure N (%) 81 (25.8)
Anemia N (%) 86 (27.4)
Smoking N (%) 199 (63.4)
Essential hypertension N (%) 278 (88.8)
Obesity: No/BMI 25-30/ BMI 30–35/ BMI 35–40 /
BMI > 40
N (%) 77/116/77/32/12 (24.5/36.9/24.6/
10.2/3.8)
doi:10.1371/journal.pone.0145723.t001
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3.2 Correlation between VDBP and KIM-1 and the study endpoints
(Tables 2, 3, 4 and 5)
Eight patients died during the follow-up time of 90 days. Death occurred at a mean of 74.5 (7–
95) days after the study entry. The causes of death were cardiovascular diseases in 4 patients,
infections in 2 patients, respiratory failure in 1 patient and other/unknown reasons in 1 patient
(Table 2). Mean VDBP levels were significantly lower in survivors (121.41± 324.45 ng/ml)
compared to deceased patients (522.01 ± 521.86 ng/ml; p = 0.040) (Table 3). Calculated VDBP/
uCr ratio confirmed this difference. Urinary KIM-1 and KIM-1/uCr 24 hrs after CM injection
as well as baseline creatinine were significantly higher in non-survivors compared to survivors
(Tables 3 and 4).
Table 2. Time to death and causes of death during the follow up.
Patient
ID




29 90 Bradyarrhythmia with asystole
42 84 Respiratory failure
124 79 Acute decompensated heart failure
133 26 Sepsis
149 95 Sudden cardiac death
164 70 Sepsis and infective endocarditis
276 48 Acute pulmonary embolism with acute
decompensated heart failure
doi:10.1371/journal.pone.0145723.t002
Table 3. Urinary concentration of VDBP and KIM-1 24 hrs after CM injection comparison in patients with and without complications. VDBP: vitamin
D binding protein, KIM-1: kidney injury molecule 1, CIN: contrast induced nephropathy, MARE: major adverse renal event, GFR: glomerulary filtration rate
estimated with the MDRD formula, N: number of patients, M: mean, SD: standard deviation, p: significance according to MANOVA, p<0.05 –is statistically
significant.
VDBP [ng/ml] KIM-1 [ng/ml]
M SD p M SD p
Whole cohort 132.23 340.05 0.161 0.19
CIN
No 134.91 355.71 0.668 0.23 0.195 0.795
Yes 169.41 335.72 0.22 0.119
Death
Alive 121.41 324.45 0.04 0.24 0.198 0.004
Dead 522.01 521.86 0.31 0.23
Dialysis
No 113.06 299.61 <0.001 0.23 0.19 0.041
Yes 613.07 700.45 0.36 0.35
Non-elective hospitalization
No 102.81 262.81 0.001 0.24 0.187 0.362
Yes 291.77 573.39 0.27 0.256
MARE
No 112.08 302 <0.001 0.18 0.175 0.009
Yes 506.16 624.61 0.32 0.321
doi:10.1371/journal.pone.0145723.t003
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CIN was diagnosed in 21 patients of our study population. Neither VDBP nor VDBP/uCr
24 hrs after CM injection were predictive for CIN. There was also no difference between KIM-
1 and KIM-1/uCr in CIN versus non CIN patients 24 hrs after CM injection (Tables 3 and 4).
11 patients in our cohort had to undergo dialysis during the follow-up period. VDBP
(Table 3) as well as VDBP/uCr (Table 4) 24 hrs after CM injection were significant predictors
of dialysis need, as their values were significantly higher in patients needed dialysis treatment
subsequently (613.07 ± 700.45 ng/ml and 169.00 ± 244.52 ng/ml/mmol/l vs 113.06 ± 299.61
ng/ml and 16.02 ± 48.05 ng/ml/mmol/l respectively). Increased urinary KIM-1 as well as KIM-
1/uCr also significantly predicted subsequent dialysis need. It has to be mentioned, that
patients that underwent dialysis had significantly higher plasma creatinine at baseline
(1.20 ± 0,34 vs. 2.26 ± 0.95 mg/dl).
Cumulative occurrence of the major adverse renal events (MARE) defined as an occurrence
of death, initiation of dialysis or a doubling of serum creatinine at follow-up seeing in16 patients
Table 4. VDBP/uCr, KIM-1/uCr 24 hrs after CM injection and baseline creatinine comparison in patients with and without complications. VDBP:
vitamin D binding protein, KIM-1: kidney injury molecule 1, uCr: urinary creatinine, CIN: contrast induced nephropathy, MARE: major adverse renal event,
GFR: glomerulary filtration rate estimated with the MDRD formula, N: number of patients, M: mean, SD: standard deviation, p: significance according to MAN-
OVA, p<0.05 –is statistically significant.
VDBP/uCr KIM-1/uCr Baseline Creatinine [mg/dl]
M SD p M SD p M SD P
Whole cohort 22.97 75.98 0.03 0.022 1.24 0.43
CIN
No 24.18 81.09 0.895 0.03 0.024 0.993 1.24 0.39 0.221
Yes 26.56 58.7 0.03 0.016 1.13 0.36
Death
Alive 18.62 61.09 <0.001 0.03 0.022 0.016 1.22 0.39 <0.001
Dead 139.57 222.29 0.05 0.039 1.86 0.98
Dialysis
No 16.02 48.05 <0.001 0.03 0.02 <0.001 1.2 0.34 <0.001
Yes 169 244.52 0.06 0.052 2.26 0.95
Non-elective hospitalization
No 16.07 54.23 0.002 0.03 0.021 0.009 1.21 0.37 0.013
Yes 54.01 130.36 0.04 0.031 1.39 0.67
doi:10.1371/journal.pone.0145723.t004
Table 5. Logistic regression analyses MARE independent variables. VDBP: vitamin D binding protein, KIM-1: kidney injury molecule 1, p<0.05 –is statis-
tically significant.
Variables B SE Wald 95% CI P
Lower Upper
VDBP 0.001 0.001 5.548 1.000 1.002 0.019
KIM-1 2.273 1.109 4.200 1.104 85.419 0.040
Age -0.014 0.029 0.216 0.932 1.044 0.642
Contrast volume -0.002 0.005 0.087 0.988 1.009 0.769
Anemia 0.539 0.198 7.373 1.162 2.529 0.007
Congestive heart failure 0.154 0.122 1.582 0.918 1.482 0.208
Diabetes mellitus -0.317 0.624 .257 .215 2.475 0.612
Renal insufﬁciency -0.448 1.140 0.155 0.068 5.960 0.694
doi:10.1371/journal.pone.0145723.t005
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of our study population could be predicted by significantly higher levels of VDBP as well as
VDBP/uCr as early as 24 hrs after CM injection (506.16 ± 624.61 ng/ml and 125.68 ± 211.62 ng/
ml/mmol/l vs 112.08 ± 302.00 ng/ml and 14.99 ± 38.10 ng/ml/mmol/l respectively). Increased
urinary KIM-1 and KIM-1/uCr ratio were significant predictors of MARE as well (Tables 3 and
4). Logistic regression analyses MARE independent variables confirmed that VDBP along with
KIM-1 and anemia were significant predictors of MARE (Table 5).
In addition, we assessed correlation between non-elective hospitalization during the 90 days
of follow-up and urinary VDBD, urinary KIM-1, VDBP/uCr and KIM-1/uCr. Statistical analy-
sis revealed that increased levels of urinary VDBD, VDBP/uCr, urinary KIM-1, KIM-1/uCr 24
hrs after CM injection together with elevated plasma creatinine concentration at baseline were
significantly higher in patients needed non-elective hospitalization during the 90 days of fol-
low-up. (Tables 3 and 4).
Discussion
To our knowledge, this is the first study demonstrating that urinary VDBP and VDBP/uCr are
biomarkers predicting dialysis need, death, non-elective hospitalization and MARE up to 90
days after contrast media exposure. With the exception of non-elective hospitalization urinary
KIM-1 24 hours after CM exposure was likewise significantly higher in patients who died,
needed dialysis or developed MARE during the follow-up of 90 days (Tables 4 and 5). Urinary
VDBP and KIM-1, however, were not related to the development of CIN.
Our results are consistent with previous reports on the urinary loss of VDBP in the setting
of renal damage in a rat adriamycin-induced nephrotoxicity model [18] as well as in the setting
of chronic kidney disease in humans [19,20]. Interestingly, urinary VDBP [14] as well as uri-
nary KIM-1 [21] were associated with interstitial inflammation independently of albuminuria
rendering VDBP an even more interesting candidate biomarker.
It was previously shown that urinary VDBP was rising with increasing severity of renal
damage, and responded by declining to renoprotective therapy [14]. In addition, urinary
VDBP is about 4-fold increased in diabetic patients with normoalbuminuria [22]. These facts
suggest that tubulointerstitial damage, considered as the final common pathway towards end-
stage renal disease (ESRD), is present at the early asymptomatic stage of chronic kidney dis-
ease. Indeed, urinary VDBP was strongly and consistently elevated in rats with adriamycin-
induced nephropathy very early in the course of the disease, before pro-fibrotic biomarkers
could even be detected [14]. In addition, increased urinary VDBP was strongly associated with
markers of tubulointerstitial fibrosis after induction of nephrosis [14].
Increased levels of urinary VDBP were significant predictors of all-cause mortality in our
study. To our best knowledge, there are no data on association between urinary VDBP and
mortality in the current literature. Nevertheless, in a number of studies, low bioavailable vita-
min D plasma concentrations were associated with higher mortality rates [23,24].
The US Food and Drug Administration approved KIM-1 as a one of the urinary biomarkers
in a panel for preclinical trials [25]. The peak of urinary KIM-1 is 24–48 hrs after onset of the
kidney injury [26,27,28,29]. These data are not in line with our results, which have shown no
significant association between increase of urinary KIM-1 and CIN. A number of studies
reported even that increased urinary KIM-1 was not significantly associated with acute kidney
injury [30,31]. Verbrugge et al. in their study on patients with acute decompensated heart fail-
ure found that urinary KIM-1 is not a reliable predictor of persistent renal impairment or all-
cause mortality, as it was shown in our study. At the same time, the ratio KIM-1/uCr may be of
value for the detection of renal injury, as it was described by Kwon et al. in patients with IgA
nephropathy. Normalizing a urinary biomarker concentration to urinary creatinine takes into
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account differences in urinary flow rate. However, if the assessed biomarker behaves exactly
like creatinine in terms of filtration, secretion and reabsorption [32], the normalized level may
be affected by differences in urinary creatinine excretion. This needs to be considered when
“normalizing” urinary biomakers to urinary creatinine concentrations.
The currently used clinical definitions of CIN are based on the short-term changes of glo-
merular function after contrast media exposure, since they use changes of GFR surrogate bio-
markers such as creatinine to define CIN. These definitions are suitable for both daily clinical
work and clinical studies. They, however, ignore alterations in tubular function although the
morphological hallmark of acute renal failure in general and CIN in particular are tubular
alterations such as tubular necrosis and tubular dilatation [33], Vitamin-D-binding protein is
filtered through the glomerulus as a 25-(OH) vitamin D 3/VDBP complex and is uptaken by
megalin receptors in the brush border of proximal tubule cells [9,11]. This is a highly specific
tubular process. Glomeruli are not involved in it. Thus our findings that urinary VDBP con-
centrations are a biomarker of major clinical outcomes for 90 days after contrast media expo-
sure but not for CIN as defined by short term alterations of GFR indicate that tubular
alterations are much closer related to long term clinical outcome then short term alteration of
GFR. The current CIN definitions describes more likely short term alterations of glomerular
hemodynamics / glomerular function, whereas tubular alterations are obviously much closer
linked to contrast media induced long term clinical consequences. This concept is supported
also by the KIM-1 data presented in this study. They likewise predict MARE but not CIN and
KIM-1 is also just of tubular origin. Our data also questions the currently used clinical defini-
tion of CIN based on short term changes in GFR. It might be more appropriate to use biomark-
ers describing tubular function to define CIN in clinical settings, since tubular alterations are
the most prominent morphological finding in CIN and as indicated by our study, tubular bio-
marker alterations might be better related to the -more important– 90 day clinical outcome
after contrast media exposure (MARE). This hypothesis, however, needs to be tested in larger
clinical studies.
Conclusion
Urinary VDBP and VDBP/uCr are promising novel biomarkers of major contrast induced
nephropathy-associated events 90 days after contrast media exposure. and may thus be usefuls
tools for diagnostics and treatment of acute renal failure after contrast media exposure.
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